MK0859
Total Payments
$15,560
Transactions
9
Doctors
5
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $15,560 | 9 | 5 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $14,600 | 4 | 93.8% |
| Travel and Lodging | $960.10 | 5 | 6.2% |
Top Doctors Receiving Payments for MK0859
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Cardiovascular Disease | Rochester, NY | $4,360 | 2 |
| Michael Davidson | Cardiovascular Disease | Chicago, IL | $4,150 | 2 |
| , MD | Cardiovascular Disease | Boston, MA | $4,150 | 2 |
| , MD | Internal Medicine | Philadelphia, PA | $2,750 | 2 |
| , M.D | Endocrinology, Diabetes & Metabolism | New York, NY | $150.00 | 1 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $15,560
Product Information
- Type Drug
- Total Payments $15,560
- Total Doctors 5
- Transactions 9
About MK0859
MK0859 is a drug associated with $15,560 in payments to 5 healthcare providers, recorded across 9 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2017. In 2017, $15,560 was paid across 9 transactions to 5 doctors.
The most common payment nature for MK0859 is "Consulting Fee" ($14,600, 93.8% of total).